Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa

Kwonjune J Seung, David B Omatayo, Salmaan Keshavjee, Jennifer J Furin, Paul E Farmer, Hind Satti, Kwonjune J Seung, David B Omatayo, Salmaan Keshavjee, Jennifer J Furin, Paul E Farmer, Hind Satti

Abstract

Background: Little is known about treatment of multidrug-resistant tuberculosis (MDR-TB) in high HIV-prevalence settings such as sub-Saharan Africa.

Methodology/principal findings: We did a retrospective analysis of early outcomes of the first cohort of patients registered in the Lesotho national MDR-TB program between July 21, 2007 and April 21, 2008. Seventy-six patients were included for analysis. Patient follow-up ended when an outcome was recorded, or on October 21, 2008 for those still on treatment. Fifty-six patients (74%) were infected with HIV; the median CD4 cell count was 184 cells/microl (range 5-824 cells/microl). By the end of the follow-up period, study patients had been followed for a median of 252 days (range 12-451 days). Twenty-two patients (29%) had died, and 52 patients (68%) were alive and in treatment. In patients who did not die, culture conversion was documented in 52/54 patients (96%). One patient had defaulted, and one patient had transferred out. Death occurred after a median of 66 days in treatment (range 12-374 days).

Conclusions/significance: In a region where clinicians and program managers are increasingly confronted by drug-resistant tuberculosis, this report provides sobering evidence of the difficulty of MDR-TB treatment in high HIV-prevalence settings. In Lesotho, an innovative community-based treatment model that involved social and nutritional support, twice-daily directly observed treatment and early empiric use of second-line TB drugs was successful in reducing mortality of MDR-TB patients. Further research is urgently needed to improve MDR-TB treatment outcomes in high HIV-prevalence settings.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Major adverse effects and clinical…
Figure 1. Major adverse effects and clinical complications during MDR-TB treatment.
Adverse effects and clinical complications were defined as in Table 2. Percentages were calculated out of a total of 76 patients.
Figure 2. Time to death during MDR-TB…
Figure 2. Time to death during MDR-TB treatment by HIV status.
This figure shows Kaplan-Meier probabilities of survival in HIV-negative (solid line) and HIV-positive (dotted line) patients. Survival is measured in days after starting MDR-TB treatment. Crosses indicate patients who did not die by the end of the follow-up period.

References

    1. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196(Suppl 1):S86–107.
    1. WHO/IUATLD. Geneva: World Health Organization; 2008. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report (WHO/HTM/TB/2008.394).
    1. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–1580.
    1. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474–481.
    1. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119–128.
    1. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318–326.
    1. Demographic and Health Survey, Lesotho. Ministry of Health and Social Welfare, Bureau of Statistics. 2004
    1. World Health Organization Global TB Database. Accessed May 11, 2008.
    1. TB and HIV Co-Infection. Ministry of Health and Social Welfare, Lesotho. 2007
    1. The Green Light Committee (GLC) Initiative. Accessed February 5, 2009.
    1. WHO. Geneva: World Health Organization; 2008. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: Emergency Update 2008 (WHO/HTM/TB/2008.402).
    1. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–645.
    1. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153–161.
    1. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402–408.
    1. Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3:e352.
    1. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159:733–740.
    1. Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis. 1992;146:849–854.
    1. Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis. 2001;5:1000–1005.
    1. Alvarez GG, Thembela BL, Muller FJ, Clinch J, Singhal N, et al. Tuberculosis at Edendale Hospital in Pietermaritzburg, Kwazulu Natal, South Africa. Int J Tuberc Lung Dis. 2004;8:1472–1478.
    1. Rich ML, Socci AR, Mitnick CD, Nardell EA, Becerra MC, et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006;10:290–296.
    1. Saravia JC, Appleton SC, Rich ML, Sarria M, Bayona J, et al. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis. 2005;9:421–429.
    1. WHO . Geneva: World Health Organization; 2009. Management of MDR-TB: a field guide. A companion document to Guidelines for the Programmatic Management of Drug-resistant Tuberculosis (WHO/HTM/TB/2008.402a).
    1. Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 2007;4:e50.
    1. Murphy RA. The emerging crisis of drug-resistant tuberculosis in South Africa: lessons from New York City. Clin Infect Dis. 2008;46:1729–1732.
    1. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet. 2007;370:1500–1507.
    1. Shin S, Furin J, Bayona J, Mate K, Kim JY, et al. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med. 2004;59:1529–1539.
    1. Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008;12:1182–1189.
    1. Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, et al. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis. 2006;10:649–655.
    1. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:648–655.
    1. Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11:1314–1320.
    1. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382–1384.
    1. Nunn P, Kibuga D, Gathua S, Brindle R, Imalingat A, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet. 1991;337:627–630.
    1. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS. 2009;20:339–345.
    1. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477.
    1. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis. 2004;8:286–298.
    1. Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, et al. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:239–246.
    1. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42:836–842.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi